Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Tong Ren Tang Technologies Co EV-to-EBITDA?
Tong Ren Tang Technologies CoTGRNF 78 EV-to-EBITDA is 4.27 as of Aug. 17, 2026, which is 18% below its 10-year median of 5.22. GuruFocus rates TGRNF with a GF Score™ of 78/100 and a GF Value™ of $0.81. The stock has 5 warning signs investors should review. Among 734 Drug Manufacturers companies, Tong Ren Tang Technologies Co ranks better than 89.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tong Ren Tang Technologies Co's enterprise value is $527.7 Mil.
Tong Ren Tang Technologies Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $123.5 Mil. Therefore, Tong Ren Tang Technologies Co's EV-to-EBITDA for today is 4.27.
The historical rank and industry rank for Tong Ren Tang Technologies Co's EV-to-EBITDA or its related term are showing as below:
TGRNF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.06 Med: 5.22 Max: 16.29
Current: 4.28
During the past 13 years, the highest EV-to-EBITDA of Tong Ren Tang Technologies Co was 16.29. The lowest was 3.06. And the median was 5.22.
TGRNF's EV-to-EBITDA is ranked better than 89.92% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs TGRNF: 4.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tong Ren Tang Technologies Co (OTCPK:TGRNF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tong Ren Tang Technologies Co's PE Ratio (TTM) for today is calculated as:
Tong Ren Tang Technologies Co's share price for today is $0.4949.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tong Ren Tang Technologies Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Tong Ren Tang Technologies Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tong Ren Tang Technologies Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tong Ren Tang Technologies Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tong Ren Tang Technologies Co's EV-to-EBITDA falls into.
Tong Ren Tang Technologies Co's current Enterprise Value is $527.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tong Ren Tang Technologies Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $123.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tong Ren Tang Technologies Co (TGRNF) has a EV-to-EBITDA of 4.27 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tong Ren Tang Technologies Co. This is 18% below median its historical median of 5.22. Over the past decade, Tong Ren Tang Technologies Co's EV-to-EBITDA has ranged from 3.06 to 16.29. According to the industry distribution chart, Tong Ren Tang Technologies Co ranks #74 out of 734 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Tong Ren Tang Technologies Co's EV-to-EBITDA too high?
Tong Ren Tang Technologies Co's current EV-to-EBITDA of 4.27 is 18% below median its 10-year median of 5.22. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 16.29. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Tong Ren Tang Technologies Co's value of 4.27 is 68% below this industry median. Based on the distribution chart, Tong Ren Tang Technologies Co ranks #74 out of 734 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tong Ren Tang Technologies Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Tong Ren Tang Technologies Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Tong Ren Tang Technologies Co ranks #74 out of 734 companies for EV-to-EBITDA. This places Tong Ren Tang Technologies Co in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.33. Tong Ren Tang Technologies Co's value of 4.27 is 68% below this benchmark. Historically, Tong Ren Tang Technologies Co's own EV-to-EBITDA has ranged from 3.06 to 16.29 over the past decade. While the company's 10-year median is 5.22 vs. the industry median of 13.33, Tong Ren Tang Technologies Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tong Ren Tang Technologies Co's current EV-to-EBITDA of 4.27 is 68% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tong Ren Tang Technologies Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tong Ren Tang Technologies Co's current EV-to-EBITDA is 4.27, which is 18% below median its own 10-year median of 5.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tong Ren Tang Technologies Co stock overvalued right now?
Tong Ren Tang Technologies Co (TGRNF) has a current EV-to-EBITDA of 4.27. The stock's GF Value™ is $0.81, compared to a current price of $0.49 — trading 38.9% below its estimated fair value. The current EV-to-EBITDA is 4.27, which is 18% below median its 10-year median of 5.22 and 68% below the Drug Manufacturers industry median of 13.33. Tong Ren Tang Technologies Co's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tong Ren Tang Technologies Co (TGRNF), the current EV-to-EBITDA is 4.27 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tong Ren Tang Technologies Co (TGRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Tong Ren Tang Technologies Co stock appears to be undervalued.
The current stock price of $0.49 is trading 38.9% below its estimated GF Value™ of $0.81.
Key valuation signals for TGRNF:
EV-to-EBITDA: 4.27 (18% below median its 10-year median of 5.22)
GF Value™: $0.81 vs. price of $0.49 (38.9% below fair value)
Industry Position: 68% below the Drug Manufacturers median (#74 of 734)
No single metric tells the full story. See the TGRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tong Ren Tang Technologies Co Ltd is engaged in the production and distribution of Chinese medicine and predominantly operates in Mainland China and Hong Kong. The operating segments derive their revenue predominantly from the manufacture and sale of Chinese medicine of the company in Mainland China and Tong Ren Tang Chinese Medicine and its subsidiaries engaged in manufacturing, retail, and wholesale of Chinese medicine products and healthcare products, and provision of Chinese medical consultation and treatments outside Mainland China and wholesale of healthcare products in Mainland China.
78GF Score
Get the complete analysis for TGRNF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGRNF has been successfully added to your 
